Loading...
A patient's low-density lipoprotein cholesterol (LDL-C) level is the primary metric by which statin treatment is titrated. Given that other cholesterol fractions — specifically apolipoprotein B (apoB) and non–high-density lipoprotein cholesterol (non–HDL-C) — are thought to predict risk for cardiovascular disease (CVD) even better than LDL-C, researchers conducted a meta-analysis to evaluate the various possibilities in statin-treated patients. A comprehensive search yielded eight randomized, controlled trials of statins in which relevant cholesterol fractions were measured and follow-up lasted ≥2 years. Among 38,000 statin recipients, roughly 6300 major cardiovascular events (e.g., myocardial infarction, stroke, unstable angina) occurred.
F…